NO940590L - Transdermal administrering av benzodiazepiner med kort eller mellomlang halveringstid - Google Patents

Transdermal administrering av benzodiazepiner med kort eller mellomlang halveringstid

Info

Publication number
NO940590L
NO940590L NO940590A NO940590A NO940590L NO 940590 L NO940590 L NO 940590L NO 940590 A NO940590 A NO 940590A NO 940590 A NO940590 A NO 940590A NO 940590 L NO940590 L NO 940590L
Authority
NO
Norway
Prior art keywords
short
benzodiazepines
benzodiazepine
lives
transdermal administration
Prior art date
Application number
NO940590A
Other languages
English (en)
Other versions
NO940590D0 (no
Inventor
Kuldeepak Sharma
Darth M Durbar
Original Assignee
Cygnus Therapeutic Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cygnus Therapeutic Systems filed Critical Cygnus Therapeutic Systems
Publication of NO940590D0 publication Critical patent/NO940590D0/no
Publication of NO940590L publication Critical patent/NO940590L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Fremgangsmåte og laminert komposltt for administrering av benzodiazepiner med kort eller mellomlang halveringstid slik som alprazolamin eller triazolam transdermalt for å behandle tilstander slik som angst i det tilfellet av alprazolam og søvnløshet i det tilfellet med triazolam. Kompositten omfatter et impermeabelt baklag og et reservoarlag som Inneholder benzodiazepin og en gjennomtrengingsforbedrer kombinert med et oppløsningsmiddel-basert akrylpolymeradhesiv der mengden av benzodiazepin og forbedreren er tilstrekke- lig til å sørge for at benzodiazepin passerer gjennom huden med en hastighet som er over ca. l pg/cm^/t.
NO940590A 1991-08-27 1994-02-21 Transdermal administrering av benzodiazepiner med kort eller mellomlang halveringstid NO940590L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/750,571 US5225198A (en) 1991-08-27 1991-08-27 Transdermal administration of short or intermediate half-life benzodiazepines
PCT/US1992/007033 WO1993003694A1 (en) 1991-08-27 1992-08-19 Transdermal administration of short or intermediate half-life benzodiazepines

Publications (2)

Publication Number Publication Date
NO940590D0 NO940590D0 (no) 1994-02-21
NO940590L true NO940590L (no) 1994-02-21

Family

ID=25018394

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940590A NO940590L (no) 1991-08-27 1994-02-21 Transdermal administrering av benzodiazepiner med kort eller mellomlang halveringstid

Country Status (10)

Country Link
US (2) US5225198A (no)
EP (1) EP0621769A4 (no)
JP (1) JPH06510049A (no)
AU (1) AU654875B2 (no)
CA (1) CA2115841A1 (no)
FI (1) FI940948A0 (no)
NO (1) NO940590L (no)
NZ (1) NZ244065A (no)
PT (1) PT100815A (no)
WO (1) WO1993003694A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225198A (en) * 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
WO1994021262A1 (en) * 1993-03-17 1994-09-29 Alza Corporation Device for the transdermal administration of alprazolam
US5635204A (en) * 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
US5580574A (en) * 1994-04-28 1996-12-03 Hoffmann-La Roche Inc. Pharmaceutical composition for transdermal delivery
US5552153A (en) * 1994-04-28 1996-09-03 Hoffman-La Roche Inc. Pharmaceutical composition for transdermal delivery
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
IL122484A0 (en) 1995-06-07 1998-06-15 Noven Pharma Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
EP1258257A3 (de) * 2001-05-15 2003-09-24 IVF Hartmann AG Hautpflegende Klebstoffzusammensetzung
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE60204229T2 (de) * 2002-12-02 2006-02-02 Schwarz Pharma Ag Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
CN100402036C (zh) * 2004-04-26 2008-07-16 袁重华 治疗失眠的涂敷剂
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
EP2230911A4 (en) * 2007-12-21 2013-07-03 Zars Pharma Inc STAMPS, FORMULATIONS, AND RELATED METHODS FOR THE TRANSDERMAL DELIVERY OF ALPRAZOLAM AND OTHER MEDICAMENTS
US10449201B2 (en) 2015-08-17 2019-10-22 Alpha To Omega Pharmaceutical Consultants, Inc. Transdermal and/or topical delivery system comprising clobazam

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987052A (en) * 1969-03-17 1976-10-19 The Upjohn Company 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
JPS6133129A (ja) * 1984-07-25 1986-02-17 Nitto Electric Ind Co Ltd 基剤組成物および外用医薬組成物
JPS61254519A (ja) * 1985-05-07 1986-11-12 Nitto Electric Ind Co Ltd ゲル状医薬製剤
US4863738A (en) * 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5252335A (en) * 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5225198A (en) * 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines

Also Published As

Publication number Publication date
WO1993003694A1 (en) 1993-03-04
NZ244065A (en) 1995-02-24
CA2115841A1 (en) 1993-03-04
FI940948A (fi) 1994-02-28
AU2488092A (en) 1993-03-16
NO940590D0 (no) 1994-02-21
US5225198A (en) 1993-07-06
JPH06510049A (ja) 1994-11-10
PT100815A (pt) 1993-09-30
EP0621769A4 (en) 1995-06-07
US5378473A (en) 1995-01-03
FI940948A0 (fi) 1994-02-28
AU654875B2 (en) 1994-11-24
EP0621769A1 (en) 1994-11-02

Similar Documents

Publication Publication Date Title
NO940590L (no) Transdermal administrering av benzodiazepiner med kort eller mellomlang halveringstid
ATA87488A (de) Mehrschichtiges transdermales therapeutisches system fuer die kombinierte applikation von oestrogen bzw. synthetischen oestrogen-wirksamen verbindungen mit synthetischen gestagenen
DE3161605D1 (en) Therapeutic system for administering drugs to the skin
CA2064687A1 (en) Method and device for administering dexmedetomidine transdermaly
EP0196769A3 (en) A novel transdermal pharmaceutical absorption dosage unit
HK1010679A1 (en) Drug-containing adhesive composite transdermal delivery device
NO895172D0 (no) Fremgangsmaate for fremstilling av et transdermalt terapeutisk system med phytostigmin som virkestoff.
ATE109357T1 (de) Transdermales estradiol als therapeutisches sytem.
IL106512A (en) Plaster for the transdermal application of steroid hormones and process for the preparation thereof
MY111688A (en) Transdermal therapeutic system comprising the active substance 17-b-estradiol (anhydous)
JPS5731611A (en) Tape or pieace pharmaceutical preparation
GR1002079B (en) System of a special structure and composition for the rapid transdermal administration of oestrogens.
EP0235259A4 (en) NOVEL TRANSDERMAL PHARMACEUTICAL DOSAGE UNIT AGAINST ANGINES AND ITS ADMINISTRATION METHOD.
PL308531A1 (en) Percutaneous therapeutic system for applying physostygmine onto skin and method of obtaining same
PL319013A1 (en) Transdermal therapeutic system containing estradiol and water bonding additives
DE59509643D1 (de) Transdermales therapeutisches system mit hydrolyseschutz
NO924926L (no) Transdermal administrering av buprenorfin
TW273516B (en) Adhesive matrix-type transdermal therapeutic set for motion sickness